Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice

J Int AIDS Soc. 2022 Jul;25(7):e25963. doi: 10.1002/jia2.25963.
No abstract available

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Diketopiperazines
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Humans
  • Implementation Science
  • Pyridones / therapeutic use
  • Rilpivirine / therapeutic use

Substances

  • Anti-HIV Agents
  • Diketopiperazines
  • Pyridones
  • Rilpivirine
  • cabotegravir